Duke Cancer Institute is a clinical research site located in Durham, North Carolina, United States 27710.
Crixeo Health Trust Score: 90/100 (GOOD). This profile has not yet been claimed by the site owner.
Duke Cancer Institute has participated in 146 clinical trials with 53 currently active.
Therapeutic areas: Relapsed or Refractory Lymphoid Malignancies, Sarcoma, Ewing, Solid Tumor.
Sponsors: OncoMed Pharmaceuticals, Inc., Oncternal Therapeutics, Inc, NanoCarrier Co., Ltd..
Trust Score: 90/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.
Duke Cancer Institute has a Crixeo Trust Score of 90/100 (GOOD). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.
Duke Cancer Institute has 146 clinical trials on record, with 53 currently active. Their work covers Relapsed or Refractory Lymphoid Malignancies, Sarcoma, Ewing, Solid Tumor.
Duke Cancer Institute has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.
Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.